| ALK | Anaplastic lymphoma kinase; |
| APOA2 | Apolipoprotein A2; |
| APOA4 | Apolipoprotein A4; |
| ASCO | American Society of Clinical Oncology; |
| BTK | Bruton’s tyrosine kinase; |
| CA 19-9 | Cancer antigen 19-9; |
| CDK4/6 | Cyclin-dependent kinase 4/6; |
| CSF-1R | Colony-stimulating factor 1 receptor; |
| CP | Chronic pancreatitis; |
| CTC | Circulating tumoral cell; |
| DDR1/2 | Discoidin domain receptor tyrosine kinase 1/2; |
| EGFR | Epidermal growth factor receptor; |
| ELISA | Enzyme-linked immunosorbent assay; |
| FFPE | Formalin-fixed paraffin-embedded; |
| FGFR | Fibroblast growth factor receptor; |
| FLT3 | Fms-related tyrosine kinase 3; |
| GAS6 | Growth arrest-specific 6; |
| Grb10 | Growth factor bound protein 10; |
| HER2 | human epidermal growth factor receptor 2; |
| Hsp27 | Heat shock protein 27; |
| IGF-1(R) | Insulin-like growth factor 1 (Receptor); |
| IMAC | immobilized metal affinity chromatography; |
| IPMN | Intraductal papillary mucinous neoplasm; |
| iTRAQ | isobaric tags for relative and absolute quantitation; |
| JAK | Janus kinase; |
| Lck | Lymphocyte-specific protein tyrosine kinase; |
| LCM | Laser capture microdissection; |
| MA | Marketing authorization; |
| MALDI-TOF | Matrix assisted laser desorption ionization-time of flight mass spectrometry; |
| MEK | Mitogen-activated protein kinase kinase; |
| MET | Hepatocyte growth factor receptor; |
| MRM | Multiple reaction monitoring; |
| MS | Mass spectrometry; |
| mTOR | Mammalian target of rapamycin; |
| NNRTI | Inhibitor of non-nucleoside reverse transcriptase; |
| PanIN | Pancreatic intraepithelial neoplasia; |
| PARP | Poly ADP ribose polymerase; |
| PDAC | Pancreatic ductal adenocarcinoma; |
| PDGFR | Platelet-derived growth factor receptor; |
| PDX | Patient-derived xenograft; |
| PI3K | Phosphatidylinositol-3-kinase; |
| PSCA | Prostate stem cell antigen; |
| pTyr | phosphorylated tyrosine; |
| OS | Overall survival; |
| PFS | Progression-free survival; |
| RANKL | Receptor activator of nuclear factor kappa-Β ligand; |
| ROS1 | C-ros oncogene 1; |
| RPPA | Reverse phase protein array; |
| RTK | Receptor tyrosine kinase; |
| Tie2 | Tyrosine kinase with immunoglobulin and EGF homology domains; |
| TIMP | Tissue inhibitor of metalloproteinase-1; |
| TiO2 | Titanium dioxide; |
| TGFβR | Transforming growth factor β receptor; |
| TK | Tyrosine kinase; |
| SILAC | Stable isotope labelling with amino acids in cell culture; |
| SMO | Smoothened kinase; |
| SRM | Selected reaction monitoring |
| VEGF(R) | Vascular endothelial growth factor (receptor); |